Literature DB >> 7926883

Radiation effects on the optic nerve observed after brachytherapy of choroidal melanomas with 106Ru/106Rh plaques.

P K Lommatzsch1, W Alberti, R Lommatzsch, F Rohrwacher.   

Abstract

From 1966 to 1990 a total of 93 juxtapapillary choroidal melanomas were treated using 106Ru/106Rh plaques with a notch for the optic nerve. The choroidal melanoma was controlled after brachytherapy in 79 cases (85%). Fourteen eyes (15%) had to be enucleated because of tumor regrowth. Eye and optic nerve phantoms were fabricated, loaded with small-volume thermoluminescent dosimeters, treated with active plaques, and the radiation dose determined at the optic disc and along the optic nerve. The median dose within the anterior optic nerve was 51.2 Gy (range 10.3-60.5 Gy). The probability of developing complete radiation optic neuropathy (RON) was 23% and 53% at 5 and 10 years, respectively. The probability of developing partial RON was 66% at 5 years and 82% at 10 years. The probability of retaining visual acuity better than 0.5 was 38% at 5 years and 26% at 10 years. No dose-response relationship could be established from the ophthalmological, morphological and functional findings. Eyes following plaque irradiation with 50 Gy or more in the center of the optic nerve experienced significant radiation optic neuropathy, other eyes did not.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926883     DOI: 10.1007/bf00195358

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  15 in total

1.  Dosimetry and physical treatment planning for iodine eye plaque therapy.

Authors:  W Alberti; B Pothmann; P Tabor; K Muskalla; K P Hermann; D Harder
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-05       Impact factor: 7.038

2.  Radiation retino- and opticopathy. A prospective study.

Authors:  M L Pigeaud-Klessens; J H Kralendonk
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

3.  Iodine-125 radiation of posterior uveal melanoma.

Authors:  S Packer
Journal:  Ophthalmology       Date:  1987-12       Impact factor: 12.079

4.  [Morphologic changes of the optic nerve after therapeutic irradiation].

Authors:  K Riedel; F H Stefani; A Kampik
Journal:  Fortschr Ophthalmol       Date:  1983

5.  Long-term results of proton beam irradiated uveal melanomas.

Authors:  E S Gragoudas; J M Seddon; K Egan; R Glynn; J Munzenrider; M Austin-Seymour; M Goitein; L Verhey; M Urie; A Koehler
Journal:  Ophthalmology       Date:  1987-04       Impact factor: 12.079

6.  Visual results following cobalt plaque radiotherapy for posterior uveal melanomas.

Authors:  A F Cruess; J J Augsburger; J A Shields; L A Donoso; J Amsel
Journal:  Ophthalmology       Date:  1984-02       Impact factor: 12.079

7.  Radiation optic neuropathy.

Authors:  G C Brown; J A Shields; G Sanborn; J J Augsburger; P J Savino; N J Schatz
Journal:  Ophthalmology       Date:  1982-12       Impact factor: 12.079

8.  Polyethylene-based water-equivalent phantom material for x-ray dosimetry at tube voltages from 10 to 100 kV.

Authors:  K P Hermann; L Geworski; M Muth; D Harder
Journal:  Phys Med Biol       Date:  1985-11       Impact factor: 3.609

9.  Radiation-induced optic neuropathy following brachytherapy of uveal melanomas.

Authors:  U Kellner; N Bornfeld; M H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-05       Impact factor: 3.117

10.  Magnetic resonance imaging of juxtapapillary plaques in cadaver eyes.

Authors:  D F Williams; W F Mieler; G J Jaffe; D M Robertson; L Hendrix
Journal:  Br J Ophthalmol       Date:  1990-01       Impact factor: 4.638

View more
  10 in total

1.  In search of a treatment for radiation-induced optic neuropathy.

Authors:  Maanasa Indaram; Ferhina S Ali; Marc H Levin
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

2.  [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].

Authors:  E Richtig; G Langmann; G Schlemmer; K Müllner; G Papaefthymiou; P Bergthaler; J Smolle
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

3.  Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.

Authors:  P Summanen; I Immonen; T Kivelä; P Tommila; J Heikkonen; A Tarkkanen
Journal:  Br J Ophthalmol       Date:  1996-08       Impact factor: 4.638

4.  Eccentric ruthenium plaque radiotherapy of posterior choroidal melanoma.

Authors:  Andrea Russo; Michela Laguardia; Bertil Damato
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-23       Impact factor: 3.117

5.  Internal resection of posterior uveal melanomas.

Authors:  P J Kertes; J C Johnson; G A Peyman
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

6.  I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30.

Authors:  H Culver Boldt; B Michele Melia; Judy C Liu; Sandra M Reynolds
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

7.  Ruthenium-106 Brachytherapy with or without Additional Local Therapy Shows Favorable Outcome for Variable-Sized Choroidal Melanomas in Korean Patients.

Authors:  Yeona Cho; Jee Suk Chang; Jin Sook Yoon; Sung Chul Lee; Yong Bae Kim; Joo Ho Kim; Ki Chang Keum
Journal:  Cancer Res Treat       Date:  2017-03-24       Impact factor: 4.679

8.  Radiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II.

Authors:  David Miguel; Jesús María de Frutos-Baraja; Francisco López-Lara; María Antonia Saornil; Ciro García-Álvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2018-08-31

9.  Changes in the micromorphology of the corneal subbasal nerve plexus in patients after plaque brachytherapy.

Authors:  Andrey Zhivov; Karsten Winter; Sabine Peschel; Oliver Stachs; Andreas Wree; Guido Hildebrandt; Rudolf Guthoff
Journal:  Radiat Oncol       Date:  2013-06-07       Impact factor: 3.481

10.  Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas.

Authors:  Lisa Tarmann; Werner Wackernagel; Domagoj Ivastinovic; Mona Schneider; Peter Winkler; Gerald Langmann
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.